Q-Line Biotec SME IPO GMP Today

GMP for Q-Line Biotec SME started at Rs 0 on 17 May 2026 and stood at Rs 133 on 29 May 2026. The sharpest single-day jump was from Rs 0 on 17 May 2026 to Rs 69 on 18 May 2026. The upward move through the subscription window usually reflects building demand across investor categories rather than a one-day spike.

Based on today's GMP, Q-Line Biotec SME IPO listing price estimate is Rs 472.00 per share (issue price Rs 343.00 + GMP Rs 129.00).

Actual listing price will be known on 29 May 2026 when the stock lists on NSE/BSE.

A GMP of around 37.6% is a strong positive signal from the grey market. Investors are pricing in a meaningful listing premium over the issue price.

GMP has moved up over the tracked period. Steady increases through the subscription window are usually a stronger signal than a single-day spike.

GMP is unofficial. Listing gain can differ on listing day.

GMP and subscription numbers often move together. When institutional and HNI demand is strong, grey market participants usually price in a higher premium. The GMP move around 18 May 2026 may reflect how the market reacted once the subscription window activity picked up after 21 May 2026.

See live figures on the Q-Line Biotec SME IPO Subscription Status page.

Q-Line Biotec SME IPO full details (financials, peers, review).

Q-Line Biotech Limited, incorporated in 2010 (originally as POCT Services Private Limited), is an Indian diagnostics and in-vitro diagnostics (IVD) enterprise. The company is actively engaged in developing, manufacturing, and marketing a diverse range of medical reagents, consumable testing kits, point-of-care (POC) devices, and automated pathology equipment. Serving diagnostic laboratories, hospitals, and medical colleges directly and through an expansive national distributor network since 2013, its operational capabilities span fields like Clinical Chemistry, Haematology, Immunodiagnostics, and Molecular Diagnostics.